Does Regence Cover GLP-1 Medications?
The 2026 Washington Guide
Regence BlueCross BlueShield GLP-1 coverage explained — from Ozempic for diabetes to Wegovy and Zepbound for weight management and cardiovascular risk.
Regence BlueCross BlueShield is one of Washington state's major commercial carriers, covering employees through large employer groups, small business plans, and individual policies across the Pacific Northwest. If you're a Regence member wondering whether your plan covers GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound, the coverage landscape shifted significantly in late 2025 — and understanding the updated policies is essential before you start treatment.
Regence updated its primary weight management GLP-1 policy (dru787) in October 2025, with the new criteria taking effect December 2025. This guide covers all current coverage pathways, the updated PA submission process, and the cardiovascular risk reduction pathway that may apply even if your plan excludes GLP-1s for obesity.
Regence GLP-1 Coverage Table
Regence coverage for GLP-1 receptor agonists depends on the indication and whether the employer's benefit plan includes anti-obesity medication coverage. The table below summarizes coverage by drug and indication under current Regence policies.
| Drug | Covered? | Key Requirements |
|---|---|---|
| Ozempic / Mounjaro Type 2 Diabetes |
Yes, PA required | T2D; HbA1c ≥7%; metformin trial; PA via CoverMyMeds or fax (888) 437-1510; Policy dru750 |
| Wegovy / Zepbound Obesity |
Plan-Dependent | AOM rider required; BMI ≥30 or ≥27 + comorbidity; Policy dru787 (updated Oct 2025, eff. Dec 2025) |
| Wegovy CV Risk Reduction |
Yes | Established CVD + BMI ≥27; separate from weight management policy; no AOM rider required |
| Zepbound Obstructive Sleep Apnea |
Plan-Dep. | BMI ≥30; sleep study required; check plan benefit for AOM rider applicability |
Regence's December 2025 Policy Update
Regence updated its GLP-1 weight management policy (dru787) in October 2025, with the revised criteria becoming effective December 2025. The update expanded coverage criteria for both the obesity and cardiovascular indications and aligned Regence's requirements more closely with current clinical evidence — including the SELECT trial data supporting Wegovy's cardiovascular benefit.
Key changes in the December 2025 update include refined BMI and comorbidity criteria, an expanded cardiovascular risk pathway, and clearer documentation requirements for lifestyle modification. The AOM rider requirement for weight management coverage remains in place — the update did not change the employer opt-in structure.
Important: If you were previously denied a GLP-1 under Regence's older dru787 criteria, the December 2025 update may make you eligible to reapply. PA submissions should reflect the updated criteria to ensure your request is reviewed under the current policy.
Prior Authorization: How to Submit to Regence
Regence has specific PA submission channels for GLP-1 medications. Using the right channel speeds up approval:
- CoverMyMeds (electronic): The fastest submission method. Regence integrates directly with CoverMyMeds for GLP-1 prior authorizations. Most providers receive a decision within 1–2 business days.
- Fax to RegenceRx: (888) 437-1510. Slightly slower than electronic submission but accepted for all PA requests.
- Approval windows: 12-month approval with annual renewal required. Regence does not grant indefinite approvals for GLP-1s.
- Ozempic dose documentation: Doses at or below 2 mg/week must be documented; higher doses may trigger separate review as Wegovy-equivalent and be evaluated under the weight management policy (dru787) rather than the diabetes policy (dru750).
The AOM Rider and Regence Weight Management Coverage
Like most commercial carriers in Washington, Regence requires employer groups to opt into anti-obesity medication (AOM) coverage as a separate rider. Without this rider, Wegovy and Zepbound for weight management are excluded from the benefit, regardless of a member's BMI, medical necessity, or comorbidities.
Policy dru787 — Regence's weight management GLP-1 policy — only governs plans that have elected AOM coverage. If your employer-sponsored Regence plan did not add the rider, no weight management GLP-1 claim will be processed. To find out whether your plan includes it, call member services or check your Summary of Benefits for exclusions related to "weight management" or "anti-obesity medications."
Weight management drugs are EXCLUDED on many Regence plans that have not opted into the AOM rider. Do not assume coverage — verify your specific benefit before starting treatment.
The CV Risk Pathway at Regence
Regence covers Wegovy for cardiovascular risk reduction under a separate clinical pathway — distinct from the weight management policy (dru787). This coverage does not require an AOM rider and applies to Regence plans that would otherwise exclude GLP-1s for obesity.
To qualify, patients must have established cardiovascular disease — a prior myocardial infarction, stroke, or peripheral arterial disease — and a BMI of 27 or higher. The PA submission must document the CVD diagnosis using appropriate ICD-10 codes and frame the clinical rationale around cardiovascular risk, not weight reduction.
Important for Regence members with heart disease: The December 2025 dru787 update explicitly expanded the CV risk pathway. If you have established CVD and BMI ≥27, Wegovy for cardiovascular risk reduction may be covered on your Regence plan even without AOM coverage.
Estimated Patient Costs
When GLP-1 coverage applies under your Regence plan, typical post-deductible out-of-pocket costs fall within these ranges. Costs vary based on your plan's specialty tier design and deductible status.
T2D Medications
Ozempic / Mounjaro. PA via CoverMyMeds or fax. Policy dru750.
Obesity / CV Risk Medications
Wegovy / Zepbound. Specialty Tier, when covered under dru787 or CV pathway.
Why Revive for Regence GLP-1 Patients
- Comprehensive lab panel: Our first-visit labs include HbA1c, lipid panel, complete metabolic panel, and CBC — satisfying the documentation requirements Regence needs for T2D (dru750) and CV risk PA submissions.
- FDA-approved medications to retail pharmacies: We prescribe FDA-approved GLP-1 medications to standard retail pharmacies — fully compatible with your Regence pharmacy benefit and formulary.
- PA management team: We submit to Regence via CoverMyMeds for fastest approval, identify which pathway (dru750, dru787, or CV risk) maximizes your approval odds, and handle appeals if needed.
- Integrated care: For patients managing metabolic syndrome, TRT, and GLP-1 therapy together, we coordinate labs, prescriptions, and monitoring under one clinical team.
Common Questions
Does Regence cover Wegovy?
It depends on your plan and indication. For obesity, Wegovy requires an AOM rider — which your employer must have elected. For cardiovascular risk reduction in patients with established CVD and BMI ≥27, Wegovy is covered separately without the AOM rider requirement. For Type 2 diabetes, Ozempic and Mounjaro are the preferred agents under Regence's diabetes policy (dru750); Wegovy is not indicated for T2D.
How long does Regence PA approval take?
Typically 1–2 business days via CoverMyMeds (electronic submission). Fax submissions to (888) 437-1510 may take slightly longer depending on volume. Regence grants 12-month approval windows, with annual renewal required. Our team handles all submission and follow-up.
What changed in Regence's December 2025 GLP-1 policy?
Regence's October 2025 update to policy dru787 (effective December 2025) expanded eligibility criteria for both the obesity and cardiovascular indications, aligned documentation requirements with current clinical guidelines, and explicitly expanded the CV risk pathway. If you were previously denied under the older criteria, it may be worth resubmitting a PA under the updated policy. Our team can review your prior denial and advise on whether a new submission makes sense.
Related GLP-1 Coverage Guides
Regence Member? Check Your GLP-1 Options.
We work with Regence to handle PA submission, labs, and formulary navigation — so you can focus on your health, not the paperwork.
Or call us: (206) 960-4770 · Seattle · Kirkland · Federal Way